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Abstract: We have recently reported that a cyclic peptide containing five tryptophan, five arginine,
and one cysteine amino acids [(WR)5C], was able to produce peptide-capped gadolinium nanopar-
ticles, [(WR)5C]-GdNPs, in the range of 240 to 260 nm upon mixing with an aqueous solution of
GdCl3. Herein, we report [(WR)5C]-GdNPs as an efficient siRNA delivery system. The peptide-based
gadolinium nanoparticles (50 µM) did not exhibit significant cytotoxicity (~93% cell viability at
50 µM) in human leukemia T lymphoblast cells (CCRF-CEM) and triple-negative breast cancer cells
(MDA-MB-231) after 48 h. Fluorescence-activated cell sorting (FACS) analysis indicated that the
cellular uptakes of Alexa-488-labeled siRNA were found to be enhanced by more than 10 folds in the
presence of [(WR)5C]-GdNPs compared with siRNA alone in CCRF-CEM and MDA-MB-231 cells
after 6 h of incubation at 37 ◦C. The gene silencing efficacy of the nanoparticles was determined via
the western blot technique using an over-expressed gene, STAT-3 protein, in MDA-MB-231 cells. The
results showed ~62% reduction of STAT-3 was observed in MDA-MB-231 with [(WR)5C]-GdNPs at
N/P 40. The integrity of the cellular membrane of CCRF-CEM cells was found to be intact when
incubated with [(WR)5C]-Gd nanoparticles (50 µM) for 2 h. Confocal microscopy reveals higher inter-
nalization of siRNA in MDA-MB-231 cells using [(WR)5C]-GdNPs at N/P 40. These results provided
insight about the use of the [(WR)5C]-GdNPs complex as a potent intracellular siRNA transporter
that could be a nontoxic choice to be used as a transfection agent for nucleic-acid-based therapeutics.
Keywords: siRNA delivery systems; cyclic peptides; gadolinium nanoparticles; intracellular
transportation; nanocomplexes
1. Introduction
Signaling pathways are a chain of reactions that precisely regulate gene expression
and lead to a controlled cell function. Within this process, RNA interference (RNAi)
modulates the gene expression process through degradation [1]. In a cellular medium, a
small double-strand RNA molecule (siRNA) moderates RNAi through association with
the RNA-induced slicing complex (RISC). However, as a therapeutic entity, siRNA is a
class of RNA molecules that elicits the knockdown of its complementary target mRNA and
consequently inhibits the expression of the corresponding protein [2]. The nature of siRNA
is therapeutically unique and offers multiple advantages, such as specificity, lower toxicity,
and high availability [3,4]. However, siRNA suffers from several drawbacks, including
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a high level of instability in the presence of peptidases, a high incidence of nonspecific
interactions with proteins, and low cellular internalization capability. Most siRNA delivery
systems have been used to facilitate siRNA’s internalization process and get through the
cell membrane via energy-dependent endocytosis [5–7].
A wide range of nonviral delivery systems including chitosan [8–11], dendrimers [12,13],
polyethyleneimines [14,15], gold nanoparticles [16,17], iron oxide nanoparticles [18], silica-
based nanoparticles [19], quantum dots [20], cell-penetrating peptides [21], and nanogels [22]
have been used for transporting siRNA molecules. One of the major methods to enhance
siRNA delivery efficiency is to employ hydrophobic particles to encapsulate them. The
United States Food and Drug Administration (FDA) approved a lipid-based nanoparticle
system for encapsulating siRNA in the treatment of polyneuropathy in patients with hered-
itary transthyretin-mediated amyloidosis [23]. Therefore, there is a significant potential to
enhance the delivery efficacy of siRNA therapeutics into cells.
To this date, gadolinium-based particles (GdNPs) showed promising potential. The
FDA have approved them for MRI imaging in cancer patients [24]. Naturally, due to the
specific chemistry of gadolinium, it can promote MRI images by reducing T1 relaxation
constant when it gets accumulated into tissues [25]. Furthermore, T1 contrast agents such as
Gd-DTPA (Magnevist) and Gd-DOTA (Dotarem) are great examples of where gadolinium
is able to create stable complexes via chelation with different ligands. One of the major
drawbacks of gadolinium complexes is the leaching issues of the nonmetabolizable Gd3+
ions. The leaked gadolinium could be accumulated in an organ such as kidney, causing
severe toxicity, leading to renal toxicity [26]. Although gadolinium particles have been
widely used in imaging procedures, their liposome-based formulations have been used
for diagnosis and chemotherapy outcomes [27,28]. Liposomes with dual functionality of
encapsulating doxorubicin and Gd through drug–metal complexation offered a higher
accumulation of Gd particles and doxorubicin in target tissues. Additionally, gadolinium-
doped layered double hydroxide/Au nanocomposites exhibited high doxorubicin loading
capacity with a pH-responsive release profile, leading to a higher release profile in the
cytoplasm [29]. Thus, the development of stable gadolinium nanoparticles (GdNPs) is a
major area of research interest.
Peptide-based delivery systems are one of the widely used platforms that were uti-
lized to assist non-permeable drugs and biologically important molecules in crossing cell
membranes [30]. Our interest has been involved in developing novel peptide-based carriers
to deliver siRNA intracellularly [31,32].
Cell-penetrating peptides (CPPs) were discovered to transport siRNA into cells effi-
ciently. Among them, cyclic peptides were found to offer multiple advantages compared
to their linear counterparts, including higher enzymatic stability and higher penetrating
properties due to their optimized orientation of engaged amino acids [33–35]. Cyclic
peptide-capped gold nanoparticles showed higher efficiency in delivering a model siRNA
compared to that of lipofectamine [36]. We also found that the intracellular transporting
potency of cyclic peptides could be improved when combined with metal nanoparti-
cles [37,38].
The specific orientation of engaged, positively charged, and hydrophobic amino acids
in the structure of the peptide create an optimized complex to interact and internalize
into the cell membrane. The combination of hydrophobic forces, positive charge, and
nanoparticles can be used for the delivery of siRNA since this molecule contains negatively
charged groups. As elaborated, metal nanoparticles and CPPs were found to be efficient
tools for the delivery of siRNA. Thus, we decided to take advantage of a system containing
both GdNPs and CPP to obtain an optimized outcome. Here, we evaluated a complex
containing a cyclic CPP with arginine, tryptophan, and cysteine with biofriendly GdNPs
for the delivery of siRNA. The potency of CP-GdNPs was examined for the delivery of
siRNA in cell-based assays.
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2. Results and Discussions
2.1. Preparation and Characterization of Peptide-GdNPs
A cyclic peptide containing eleven amino acids [CWRWRWRWRWR] [(WR)5C] (1)
was synthesized using solid-phase peptide chemistry (Figure 1) according to the previously
reported procedure [39].
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Figure 1. Chemical structures of the cyclic peptide [(WR)5C] 1.
The structure and morphology of [(WR)5C]-GdNPs were investigated using trans-
mission electron microscopy (TEM) as recently reported by us [39]. It was found that
[(WR)5C]-GdNPs are presented as star-shape particles with coacervates structure in size
range of 240–260 nm. It was proposed that the involved amino acids in the structure gener-
ated and capped Gd s. This behavior of the peptide was due to the presence of positively
charged arginine and hydrophobic tryptophan amino acids. Figure 2a,c demonstrates the
morphologies of [(WR)5C]-GdNPs as previously reported at a lower magnification [39].
However, it was observ that upon mixing [(WR)5C]-GdNPs with the siRNA molecule,
Figure 2b,d, the structure was changed. As it is shown, the space between gadolinium
nanoparticle becomes wider and generate cavities suggesting the incorporation of siRNA.
At the same time, the metal nanoparticles become smaller after the engagement with the
siRNA molecules. Alternatively, the star-shaped nanoparticle formation could be due to
aggregated sheets formation. Additional investigations are required to study the behavior
of the nanoparticles combined with siRNA to discover the involved forces.
2.2. Formation of Peptide—Nanoparticles and siRNA Complexes and Their Binding Affinity
Peptide–nanoparticles were mixed with siRNA to make peptide–nanoparticle–siRNA
complexes. The concentration of siRN was kep fix d in all the experiments, while the
peptide concentration was increased to increase the N/P ratio. The binding capacity of the
scrambled siRNA with the peptide was determined by the SYBR Green II dye exclusion
method. Finally, the ratio required for 50% binding (BC50) as calculated based on the line
equation of the linear portion of the curve under these experimental conditions. The BC50
was determined to be 0.044, showing the existence of a decent binding affinity between
the siRNA and peptide-based GdNPs from a set of triplicates in the experiment (Figure 3).
Multiple elements, including positively charged arginine amino acids in the structure
of the peptide and the negatively charged phosphates of the siRNA could be involved
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in the binding affinity. The results obtained are consistent with the previous reports of
tryptophan- and arginine-containing peptides from our group [40,41].
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2.3. Zeta Potential of Peptide-GdNPs
The Zeta potential values of the [(WR)5C] and [(WR)5C]-GdNPs alone was determined
according to the concentrations that were used in making complexes with siRNA (Figure 4).
The results indicated that [(WR)5C] at 14 µM (corresponding to the concentration of the
peptide in the complex at N/P 40) has a zeta potential value of +31.7 mV and the zeta
potential for [(WR)5C] at 28 µM (corresponding to the concentration of the peptide in the
complex at N/P 80) was 36.5 mV. The zeta potential values of [(WR)5C]-GdNPs at 14 µM
and 28 µM were 30 mV and 34 mV, respectively. Compared to the [(WR)5C] peptide, the
zeta potential values of [(WR)5C]-GdNPs were a slightly reduced (Figure 4). This slight
decrease could be attributed to the structure and assembly of [(WR)5C]-Gd. A similar
trend was observed in the complexes of the peptides with siRNA. For instance, the siRNA
alone showed a ZP of approximately −15 mV; the negative charge of the ZP is due to the
presence of phosphate groups in the siRNA. Both [(WR)5C] and [(WR)5C]-Gd showed a
positive zeta potential value that can be attributed to the presence of positively charged
amino groups of arginine in the peptide structure. Furthermore, the Zeta potential value
points to the stability of the complexes in the solution form.




Figure 4. Zeta potential of [(WR)5C] and [(WR)5C]-GdNPs at different concentrations alone and complexed with siRNA at 
different N/P ratios (if p < 0.01 then **). 
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triple-negative breast cancer (MDA-MB-231) cells. The cytotoxicity assay was performed 
by standard MTS method in which the cells were treated with varying concentrations in 
a range of 5 to 100 µM and the cells were incubated for 48 h. The results indicated that the 
peptide and peptide-based gadolinium nanoparticles, [(WR)5C]-GdNPs did not exhibit 
significant cytotoxicity (~93% cell viability at 50 µM) in CCRF-CEM and MDA-MB-231 





















Figure 4. Zeta potential of [(WR)5C] and [(WR)5C]-GdNPs at different concentrations alone and
complexed with siRNA at different N/P ratios (if p < 0.01 then **).
2.4. Cytotoxicity of Peptide-GdNPs
The toxicity of [(WR)5C]-GdNPs was evaluated in human leukemia (CCRF-CEM) and
triple-negative breast cancer (MDA-MB-231) cells. The cytotoxicity assay was performed
by standard MTS method in which the cells were treated with varying concentrations in a
range of 5 to 100 µM and the cells were incubated for 48 h. The results indicated that the
peptide and peptide-based gadolinium nanoparticles, [(WR)5C]-GdNPs did not exhibit
significant cytotoxicity (~93% cell viability at 50 µM) in CCRF-CEM and MDA-MB-231 cell
lines (Figure 5a,b).
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2.5. Evaluation of Peptide-GdNPs as olecular Transporters
To monitor the ability of peptide-GdNPs for the delivery of siRNA molecules, a model
experiment using Alexa-488-labeled scrambled siRNA was designed. Using the flow
cytometry method, the intracellular uptake of Alexa-488-labeled scrambled siRNA was
quantified in the absence and presence of [(WR)5C]-GdNPs. Traditionally, the intracellular
delivery of siRNA has been challenging due to the specific size of nucleic-acid-based drugs
and the presence of negatively charged groups. Here, the delivery of a model siRNA
(36 nM) was evaluated when combined with [(WR)5C]-GdNPs and compared with that of
siRNA alone in CCRF-CEM and MDA-MB-231 cells and different N to P ratios, where N
represents the number of moles of ionizable nitrogen in the peptide and P represents the
number of moles of phosphate in the siRNA. Gadolinium particles alone, free Alexa-labeled
siRNA, and the nontreated cells were used as a negative control, while previously reported
C20-CGKRK [25] peptide was used as a positive control for this assay. The analysis of
Pharmaceuticals 2021, 14, 1064 7 of 16
fluorescence-activated cell sorting (FACS) results showed that the cellular uptake of Alexa-
488 siRNA was enhanced when loaded on [(WR)5C]-GdNPs by 10 folds compared to
siRNA alone in CCRF-CEM and MDA-MB 231 cells (Figure 6a,b). It should be mentioned
that [(WR)5C]-GdNPs and the siRNA were mixed and incubated for 30 min to increase
their binding affinity. FACS data suggested that [(WR)5C]-GdNPs could potentially be used
as a carrier system to deliver siRNA intracellularly. Moreover, gadolinium particles alone
did not show any potential to deliver siRNA into cells (both CCRF-CEM and MDA-MB-231
cells), suggesting that the presence of the cyclic peptide is vital for their function.





Figure 6. (a) Cellular uptake of Alexa-488 siRNA in the presence of [(WR)5C] and [(WR)5C]-GdNPs at different ratios after 
6 h incubation in (a) CCRF-CEM cells (ns = non-significant, if p < 0.0001 then ****) and (b) in MDA-MB-231 cells (ns = 
nonsignificant, if p < 0.0001 then ****). 
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enhanced the siRNA uptake by a factor of two compared to the peptide alone. This part 
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cles are critical for the function of the system. 
A similar pattern was observed in MDA-MB-231 cells. The intracellular uptake of 
siRNA was enhanced to the highest when peptide and gadolinium nanoparticles were 
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pared to that of siRNA alone. This uptake was improved further when gadolinium nano-
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tide alone can improve the uptake of the siRNA compared to that of siRNA alone. How-
ever, when the peptide was combined with GdNPs, the transporting efficiency was max-
imized, suggesting the importance of gadolinium nanoparticles. Furthermore, as it is 
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data suggested that the cyclic peptide and gadolinium nanoparticles complexes are able 
Figure 6. (a) Cellular uptake of Alexa-488 siRNA in the presence of [( R)5C] and [(WR)5C]-GdNPs at different ratios
after 6 h incubation in (a) CCRF-CEM cells (ns = non-significant, if p < 0.0001 then ****) and (b) in MDA-MB-231 cells
(ns = nonsignificant, if p < 0.0001 then ****).
As it is shown in Figure 6a, the cellular uptake of the siRNA did not improve in the
presence of gadolinium chloride alone, significantly suggesting that the presence of peptide
is necessary for their function. At the same time, peptide alone improved the uptake
of siRNA compared to that of the free siRNA. However, the [(WR)5C]-GdNPs complex
enhanced the siRNA uptake by a factor of two co pared to the peptide alone. This part of
the results suggested that the presence of both the peptide and gadolinium nanoparticles
are critical for the function of the system.
A similar pattern was observed in MDA-MB-231 cells. The intracellular uptake of
siRNA was enhanced to the highest when peptide and gadolinium nanoparticles were
combined. The results proved that although the [(WR)5C] peptide is necessary for in-
tracellular uptake of the siRNA, gadolinium nanoparticles are the major elements that
enhance the siRNA uptake. T e availability and accessibility of multiple binding sites
allow the formation of strong bonds between gadolinium nanoparticles and cyclic peptides.
Combined forces induced by amino acids provide the cyclic-peptide-based nanocarrier to
be able to entrap siRNA molecules efficiently. In addition, their cyclic nature equipped the
carrier with a higher level of stability compared to their linear counterparts. [(WR)5C] con-
tains tryptophan, a gi ine, a d cyst ine that could offer hydroph bic for es, electrostatic
interactions, and covalent bindings, respectively. The presence of positively charged amino
acids helps the delivery system to bind with negatively charged siRNA, and at the same
time, bind with negatively charged elements in the structure of the cell membrane. Here,
the presence of the cyclic peptides enhanced the intracellular uptake of siRNA compared
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to that of siRNA alone. This uptake was improved further when gadolinium nanoparticles
were added to the complex. Moreover, it was found that the presence of the peptide
alone can improve the uptake of the siRNA compared to that of siRNA alone. However,
when the peptide was combined with GdNPs, the transporting efficiency was maximized,
suggesting the importance of gadolinium nanoparticles. Furthermore, as it is shown in
Figure 6a,b, the cellular uptake of siRNA was improved slightly by [(WR)5C]-GdNPs at
N/P 80 compared to that of [(WR)5C]-GdNPs N/P 40. At the same time, the peptide alone
complexes such as [(WR)5C] N/P 40 and [(WR)5C] N/P 80 were able to enhance the siRNA
uptake compared to that of siRNA alone. Overall, [(WR)5C]-GdNPs at N/P 80 was able to
improve the cellular uptake by approximately 1.5–2 folds as compared to [(WR)5C] at N/P
80 in both cell lines. Their transporting ability were found to be in a similar range of a fatty
acylated CGKRK peptide (C20-CGKRK at N/P 40). This piece of data suggested that the
cyclic peptide and gadolinium nanoparticles complexes are able to entrap and transport the
siRNA molecule intracellularly. It should be mentioned that higher cellular uptake does not
directly represent the bioavailability of the cargo molecule. It was previously reported that
the various pathways are responsible for the cellular internalization of peptides containing
arginine and tryptophan amino acids [33–39].
2.6. Protein Quantification (Western Blot)
To evaluate the protein silencing efficiency of the delivered siRNA, STAT-3 protein was
targeted in triple-negative breast cancer cells, MDA-MB-231. Protein silencing efficiency
of control peptide and peptide-GdNPs was assessed by western blot analysis. The results
indicated that [(WR)5C]-Gd NPs reduced the expression of STAT-3 by more than 60% when
the GdNPs:[(WR)5C] ratio was 40. A similar pattern was observed by 55% knockdown in
the presence of a [(WR)5C]-Gd NPs at N/P ratio of 80 (Figure 7). The results are consistent
with cellular uptake findings described earlier (Figure 8).
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2.8. Confocal Microscopy Imaging
Further confocal microscopy imaging was conducted to visualize the intracellular
uptake of Alexa 488-siRNA. MDA-MB-231 cells were treated with Alexa 488-siRNA alone
and Alexa 488-siRNA/[(WR)5C]-GdNPs complex at N/P 40. The results were compared
and visualized using confocal microscopy (Figure 10). Cells that were treated with Alexa
488-siRNA/[(WR)5C]-GdNPs showed a higher fluorescence signal compared to that of
Alexa 488 alone, suggesting that peptide-based gadolinium nanoparticles facilitate the
internalization process. A Texas Red phalloidin solution and DAPI were used to stain the
cell membrane and nucleus, respectively. As shown in Figure 10, the siRNA alone was
not able to internalize to the selected cells. However, the presence of [(WR)5C]-GdNPs
enhanced the siRNA uptake in MDA-MB-231 cells.
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3. Materials and Methods
Starting material for the preparation of peptide-based gadolinium nanoparticles was
previously described [39]. Silencer® Negative Control #1 siRNA, Catalog #: AM4635-
AM4636 was purchased from Applied Biosystems, Ambian Inc., USA. Negative control
siRNAs, the siRNAs with sequences that d not target any gene product—are essential
for determining siRNA transfection efficiency and to control for the effects of siRNA
delivery. We used this siRNA for performing binding affinity, DLS experiments, and flow
cytometry experiments. In addition, Hs_STAT3_7 FlexiTube siRNA was purchased from
QIAGEN LLC, USA. The target sequence was 5′-CAGCCTCTCTGCAGAATTCAA-3′, the
s nse strand was 5′-GCUUCUCUGCAGAAUUCAATT-3′ and the antisense strand was
5′-UUGAAUUCUGCAGAGAGGCTG-3′. STAT-3 (124H6) Mouse mAb #9139 and GAPDH
(D4C6R) Mouse mAb #97166 were purchased from Cell Signaling Technology (CST), USA
for the western blotting experiment. Horseradish peroxidase (HRP)-linked secondary
antibody was purchased from Abcam Inc., USA. Mini-PROTEAN TGX stain-free precast
gels and Trans-Blot T rbo Mini 0.2 µm PVDF transfer packs #1704156 were purch sed from
Bio-Rad Inc., Hercul s, CA, USA. All other r agents used for western blotting experiments
were purchased from Bio-Rad Inc., Hercules, CA, USA.
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3.1. Synthesis of Cyclic Peptide [CWRWRWRWRWR] (1)
The peptide was synthesized according to the previously reported procedure using
Fmoc/tBu solid-phase peptide synthesis. The peptide was purified by reverse-phase high-
performance liquid chromatography (RP-HPLC) and confirmed by matrix-assisted laser
desorption/ionization time of flight (MALDI-TOF) mass spectrometry [39].
3.2. In Situ Preparation of Cyclic [(WR)5C]-GdNPs
The in situ synthesis of peptide-capped GdNPs was conducted in the aqueous solution.
Two solutions, including 1 mL of [(WR)5C] (10 mM) and 1 mL of GdCl3 (10 mM) in water,
were mixed within a glass container. The mixture was mixed for 2 min using a vortex. The
color and temperature of the product did not change upon mixing. The mixed solution
was monitored for 8 h and remained colorless.
3.3. Complex Formation of Cyclic [(WR)5C]-GdNPs/siRNA Complexes, Binding Affinity,
and BC50
The complex of [(WR)5C]-GdNPs and siRNA were formed through physical mixing.
Appropriate volumes of [(WR)5C]-GdNPs and siRNA solution was mixed in presence of
HBSS buffer to obtain the different N/P ratios. siRNA concentration was constant at 36 nM
whereas the maximum concentration of [(WR)5C]-GdNPs was 28 µM. The concentration
of [(WR)5C]-GdNPs is well below the cytotoxic concentration. N to P ratio is commonly
used to determine the ratio of the peptide to siRNA. N refers to the number of moles of
ionizable nitrogen present in the peptide whereas the P represents the number of moles of




(number o f moles o f peptide× number o f ionizabale nitrogens)
(number o f moles o f siRNA× 48)
The mixture was prepared through vigorous physical mixing via vortex. The mixture
complex was incubated for 30 min before any assays to obtain a satisfactory binding.
The binding capacity of the scrambled siRNA (AM4635 negative control siRNA No 1,
Thermo Fisher Scientific, Waltham, MA, USA) with the peptide was determined by SYBR
Green II dye exclusion method [32]. Briefly, the stock solutions of 5 µM and 50 µM of the
peptides was prepared using RNase free water. Also, the solution of scrambled siRNA
(892.5 nmol/L) was prepared using DNase/RNase free water. siRNA peptide complexes
were prepared at N/P ratios 0, 0.05, 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, and 40 in 1 mL tubes
according to the previously reported procedure [42].
After a 30 min incubation at room temperature to make complexes of siRNA with pep-
tide nanoparticles, 200µL of SYBR Green II solution (1:10,000 dilution in water) was added
to the complexes. The fluorescence of the samples was quantified in a 96-well black plate
(λ excitation: 485 nm, λ emission: 527 nm) to determine the proportion of unbound siRNA.
The percentage of siRNA bound to the peptide was plotted against the peptide/siRNA
(N/P) ratio. Finally, the ratio required for 50% binding (BC50) was calculated based on the
line equation of the linear portion of the curve under these experimental conditions. To
calculate the percentage of siRNA bound to peptide-based gadolinium nanoparticles, the
following equation was used
%siRNA binding = 100− f luorescence signal o f the complex
f luorescence signal f or f ree siRNA
× 100
3.4. Zeta Potential
Zeta potential was measured for [(WR)5C], [(WR)5C]-GdNPs, and its complexes
with siRNA at 40 V using disposable folded capillary cells (DTS1070 Malvern Nano ZS
Zetasizer, Westborough, MA, USA). The calibration of the instrument was performed by
transfer standard DTS 1235. The zeta potential of siRNA alone at 36 nM concentration was
determined. The same concentration of siRNA was used in all the subsequent analyses.
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N/P ratio 40 and 80 were selected for the determination of the zeta potential of siRNA
complexes with the [(WR)5C] and [(WR)5C]-GdNPs. The concentration of the peptides
was 14 µM in the case of N/P 40, while it was 28 µM in the case of N/P 80. Individual zeta
potentials were determined through the Smoluchowski approximation. All measurements
were performed at least three times, and results were checked against the quality standard
of the instrument.
3.5. Transmission Electron Microscopy (TEM)
TEM imaging of [(WR)5C]-GdNPs samples were done according to our reported
method [39]. The [(WR)5C]-GdNPs samples were obtained by using a drop of a solution
of [(WR)5C]-GdNPs (5 mM) in water. The drop was placed on an ultrathin carbon type-A
400-mesh copper grid and left overnight to dry. The process of imaging was carried out by
EAG Laboratories (Sunnyvale, CA, USA) using a FEI Techni TF-20 operated at 200 kV in
bright-field TEM mode.
3.6. Cell Culture
CCRF-CEM cells (ATCC No. CCL-119) and MDA-MB-231 cells (ATCC No. HTB-26)
were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA).
Cell culture supplies were provided by Fisher Scientific (Pittsburgh, PA, USA). RPMI-16
and DMEM media were used for the proliferation of CCRF-CEM and MDA-MB-231 cells,
respectively. The medium was supplemented with fetal bovine serum (FBS, 10%) and
penicillin–streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in
0.9% NaCl, 1%). The cells were incubated in a humidified atmosphere of 5% CO2 and 95%
air at 37 ◦C.
3.7. Cytotoxicity Assay of [(WR)5C]-GdNPs
CCRF-CEM (50,000) and MDA-MB-231 (10,000) cells were seeded separately in a
96-well plate in 100 µL of media. They were incubated for 24 h before the experiment.
Since the CCRF-CEM cells are nonadherent, the RPMI medium was not replaced. After the
cells had settled down, the compounds including [(WR)5C], [(WR)5C]-GdNPs, and GdNPs
were added to the cells at various concentrations (5 µM to 100 µM). A similar procedure
was carried out in MDA-MB-231 cells. After treatment, the plates were incubated for
48 h at 37 ◦C in a humidified atmosphere of 5% CO2. Following 48 h of treatment, 20 µL
of CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) was added to
each well using a multichannel pipette. The plates were incubated for 2 h at 37 ◦C in
a humidified atmosphere of 5% CO2 and 95% air. The treated plates were read at the
absorbance of 490 nm using a SpectraMax M5 Spectrophotometer. The absorbance of
treated cells was compared to untreated cells (as 100% viability), and the percent of cell
viability was calculated for each concentration of compounds. DMSO (35%) was used as a
positive control for this assay [39].
3.8. Flow Cytometry Studies
The flow cytometry assay was used to quantify the intracellular uptake of the Alexa-
488-labeled siRNA in CCRF-CEM and MDA-MB-231 cells. A quantity of 1 × 107 cells per
well were seeded in a 6-well plate. The medium was selected to be RPMI in CCRF-CEM
cells while it was DMEM in MDA-MB-231 cells. A solution of [(WR)5C]-GdNPs and a
solution of Alexa-488-labeled scrambled siRNA were mixed to obtain complexes with
GdNPs: [(WR)5C] ratios of 40 and 80. The final siRNA concentration was 36 nM, and the
maximum concentration of the compounds ([(WR)5C] and [(WR)5C]-GdNPs) was 28 µM.
The mixture was incubated for 30 min in an ice bath to cause the formation of a complex.
Then, the complex was treated with the cells. Previously reported peptide C20-CGKRK
complexed with siRNA at N/P 40 was used as a positive control, whereas nontreated cells,
Alexa-488-labeled scrambled siRNA (36 nM) and GdCl3 -siRNA complexes, were used as
negative controls. The cells were incubated with their treatments for six hours at 37 ◦C. The
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incubated cells were removed after six hours and were digested with 0.25% trypsin/EDTA
(0.53 mM) for 5 min. This wash removes any membrane-bound-labeled siRNA and artificial
surface binding. This process was followed by another two rounds of washing cells with
PBS. Flow cytometry (BD-FACSVerse; BD Biosciences; San Jose, CA, USA) was used to run
the samples. The analysis of uptake was processed based on formerly reported techniques
and settings [35].
3.9. Protein Quantification (Western Blot)
The western blot method was used to determine the expression of the target protein.
A radioimmuno precipitation assay (RIPA) buffer was used for the cell lysis process based
on the standard protocol. The cells were incubated with siRNA. Trypsin was used to collect
the cells after 48 h. They were centrifuged at 600–800 rpm for 5 min. The cells were filtered
and washed with PBS (×3). A RIPA buffer (100 µL) was used for cells resuspension (25 µL).
The lysates were incubated in ice (1h). The tubes were then centrifuged for 15 min at
12,000× g (at 4 ◦C). A BSA assay was used to determine the protein concentration. The
reagent (50:1, A:B, 200 µL) was added to 25 µL of the standard sample. All samples were
tested in triplicate. The rest of the assay was carried out based on our previously reported
protocol [30].
3.10. Membrane Integrity Test
CCRF-CEM cells were plated at 1 × 106 cells/well in 6-well plates. They were treated
with a solution of [(WR)5C]-GdNPs (50 µM) in serum-free media for 2 h at 37 ◦C. Cells
were washed twice with trypsin and PBS, after 2 h of incubation. The analysis procedure
was carried out according to our formerly reported method [37].
3.11. Confocal Microscopy Imaging
MDA-MB-231 cells were cultured and prepared in DMEM containing 10% FBS and
1% Penicillin/Streptomycin antibiotics. In a 6-well plate, cover slips were placed, and the
cells were incubated on top of that for 24 h to reach confluency. Then, the cell medium was
replaced by the treatments containing AF488-siRNA alone and [(WR)5C]-GdNPs/AF488-
siRNA complex at N/P ratio of 40. After incubating for 6 h, the cells were washed with
PBS three times. A fixing solution containing 3.7% formaldehyde in PBS was added to
the cells and maintained for 10 min. The cells were rinsed three times in PBS for 5 min.
To stain the cell membrane, a Texas Red phalloidin solution (40 µL and 10 mg BSA in
10 mL of PBS) was added to the cells and incubated at room temperature for 1 h. The cells
were then washed 3 times with PBS for 5 min. One drop of DAPI was added to a slide to
stain the nucleus, and the coverslips were placed face down without air bubbles and were
stored overnight, away from light to dry. Once dry, a Nikon A1R high-definition resonant
scanning confocal microscope and NIS-Elements software (AR 4.30.02, 64 bit) were used to
image the cells.
3.12. Statistical Analysis
To determine the statistical significance of the cellular uptake results and western
blotting data, one way ANOVA test was carried out with Dunnett’s test for multiple
comparisons using GraphPad prism version 9.1.2. For the Statistical analysis of Zeta
Potential results, student t-test was employed using the same software. siRNA-treated cells
were considered as controls and compared with siRNA/vehicle combinations. p value was
determined and included in the figures.
4. Conclusions
A new nanosized complex containing a cyclic peptide and gadolinium nanoparticles
were synthesized and fabricated for intracellular siRNA delivery. The peptide and the NPs
showed an avid binding capacity to siRNA with a BC50 value of 0.044 suggesting decent
binding capability. The cytotoxicity profile of the compounds evaluated to significantly
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non-toxic (~7% cytotoxicity) at 50 µM concentrations in both MDA-MB-231 and CCRF-
CEM cells. A positive zeta potential of approximately 42 mV reflects the stability of NPs.
TEM microscopy revealed the size of NPs to be in a range of 240 to 260 nm.
Furthermore, flow cytometry results showed that [(WR)5C]-GdNPs are efficient to
transport a negatively charged cell-impermeable siRNA molecule intracellularly. [(WR)5C]-
GdNPs showed more siRNA intracellular uptake in both MDA-MB-231 and CCRF-CEM
cells compared to that of siRNA alone. The expression of STAT-3 protein was decreased in
the presence of [(WR)5C]-GdNPs in MDA-MB-231 cells. The data indicated a significantly
reduced expression of STAT-3 (>55%), which reflects the adequate intracellular uptake of
intact STAT-3 siRNA with consequent degradation of STAT-3 mRNA causing the reduced
expression of STAT-3 protein. This investigation offered that the cell-penetrating peptide-
based gadolinium nanoparticles can be safely used as a transfection agent for siRNA
and can be investigated for other nucleic-acid-based therapies such as microRNAs or
CRISPR/Cas9. Further studies are needed to assess their potential as a nontoxic nucleic
acid delivery agent.
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